Brian Taylor Slingsby bought $3.5M of MLYS
director, owner at Mineralys Therapeutics, Inc.. 259,259 shares at an average of $13.50, traded Mar 13, 2025, filed Apr 25, 2025.
Score components
- +15RoleDirector
- +25Trade size$3.5M at market
- 0Relative to holdingsHoldings up 3.0%
- 0Price contextNear the top of the 52-week range
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000052, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 13, 2025 | POpen-market purchase Common Stockindirect: See Footnote | +259,259 | $13.50 | $3.5M | 8,903,838 | Apr 25, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 16Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $409k 11,367 shares | -12% | |
| 56Moderate | Mineralys Therapeutics, Inc. | Srinivas Akkaraju director | $15M 588,235 shares | - | |
| 49Moderate | Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $30M 1,176,470 shares | +27% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $147k 11,365 shares | -11% | |
| 65Notable | Mineralys Therapeutics, Inc. | Adam Scott Levy CFO and Secretary | $1.1M 73,678 shares | -36% | |
| 33Weak | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $230k 15,884 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.